STOCK TITAN
  1. Home
  2. News
  3. RPTX

Repare Therapeutics Inc. - RPTX STOCK NEWS

Welcome to our dedicated page for Repare Therapeutics news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics stock.

Repare Therapeutics Inc (RPTX) is a clinical-stage biotechnology company pioneering precision oncology therapies through its synthetic lethality platform and CRISPR-enabled target discovery. This page aggregates official announcements, research breakthroughs, and strategic developments critical for understanding the company's progress in developing targeted cancer treatments.

Investors and researchers will find comprehensive updates on clinical trial milestones, regulatory filings, and scientific collaborations. The curated news collection includes updates on therapeutic candidates, partnership agreements, and peer-reviewed research findings, providing a centralized hub for tracking RPTX's contributions to oncology innovation.

Key content areas cover clinical-stage developments, research publications, and strategic partnerships that demonstrate the company's scientific rigor. All materials are sourced from verified corporate communications and reputable industry publications to ensure reliability.

Bookmark this page for streamlined access to Repare Therapeutics' latest advancements in CRISPR-based drug discovery and precision oncology solutions. Check back regularly for real-time insights into their mission to develop therapies targeting genetic vulnerabilities in cancer cells.

News

Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones

Rhea-AI Summary
Repare Therapeutics Inc. (RPTX) provides a corporate update and highlights key milestones anticipated in 2024. The company has advanced its pipeline significantly in 2023, presenting strong data from key programs such as lunresertib in combination with camonsertib, and camonsertib in combination with PARP inhibitors. Repare aims to expand its pipeline to four clinical-stage programs by the second half of 2024 and expects to share data readouts from ongoing studies of lunresertib combinations. The company also disclosed its partnership with Debiopharm to explore the potential clinical synergy of Debio 0123, a highly selective clinical WEE1 inhibitor, and lunresertib. Additionally, Repare announced key milestones anticipated in 2024, including the initiation of several Phase 1 studies and the reporting of data from ongoing studies. The company ended 2023 with approximately $223 million in cash, cash equivalents, and marketable securities, which is anticipated to fund planned operations into mid-2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.32%
Tags
none
-
News

Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

Rhea-AI Summary
Repare Therapeutics Inc. (RPTX) collaborates with Debiopharm to investigate the combination of lunresertib, a PKMYT1 inhibitor, and Debio 0123, a WEE1 inhibitor, in a new arm of Repare’s ongoing global MYTHIC study. The Phase 1/1b clinical trial is anticipated to initiate in the first half of 2024. The collaboration aims to explore the synergy between the two compounds and share all costs equally. The combination has shown highly synergistic and promising preclinical data, demonstrating potential transformative benefit to patients with high unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.21%
Tags
partnership
-
News

Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans

Rhea-AI Summary
Repare Therapeutics Inc. (Nasdaq: RPTX) announces the establishment of new Automatic Securities Disposition Plans (ASDPs) by its executive officers in accordance with U.S. and Canadian securities legislation. The ASDPs permit the orderly disposition of up to 929,670 common shares of Repare over approximately 15 months at prevailing market prices, with clear trading parameters and restrictions to prevent the use of material non-public information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
none
News

Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor

Rhea-AI Summary
Repare Therapeutics Inc. (Nasdaq: RPTX) announces the development of RP-1664, a potent PLK4 inhibitor, and RP-3467, a Polθ inhibitor, with promising preclinical data. RP-1664 shows synthetic lethality in TRIM37-high tumors, while RP-3467 demonstrates complete regressions in combination with PARPi and anti-tumor activity with RLT and chemotherapy. Clinical trials for RP-1664 and RP-3467 are expected to start in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.66%
Tags
clinical trial
-
News

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Repare Therapeutics Inc. (RPTX) reported positive initial data from the ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, including an overall RECIST response rate of 50% in patients with heavily pre-treated gynecological tumors. They also announced a conference call and webcast to discuss the latest data from their preclinical programs and overall pipeline on November 15th, 2023 at 8:00 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.83%
Tags
earnings
-
News

VedaBio Unveils World Class Scientific Advisory Board

Rhea-AI Summary
VedaBio, a biotechnology company, announced the formation of its scientific advisory board with world-class experts. They have unveiled the CRISPR Cascade™, a platform that delivers near-instant detection of analytes with best-in-class accuracy, backed by an initial funding of over $40 Million. The SAB members include Dr. Rashid Bashir, Dr. Daniel Durocher, Dr. Patrick Hsu, and Dr. David Perlin, who bring extensive expertise to the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
management
News

Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast

Rhea-AI Summary
Repare Therapeutics Inc. will host a live webcast to present the latest data from its ongoing preclinical programs, RP-1664 and RP-3467, on November 15 at 8:00 a.m. ET. The webcast will be available on the Investor section of the Company’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
conferences
-
News

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary
Repare Therapeutics Inc. announced that its senior management team will participate in two investor conferences in November. The first conference is the Stifel 2023 Healthcare Conference on November 14th at 8:35 a.m. Eastern Time in New York, NY. The second conference is the Piper Sandler 35th Annual Healthcare Conference on November 28th at 10:30 a.m. Eastern Time, also in New York, NY. The fireside chats will be webcasted live on the company's website, with a replay available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.7%
Tags
conferences
-
News

Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib

Rhea-AI Summary
Repare Therapeutics reports positive initial data from Phase 1 MYTHIC clinical trial evaluating lunresertib and camonsertib combination for treating solid tumors. Encouraging safety and tolerability profile observed. Overall response of 33.3% across all tumor types and 50% RECIST response in heavily pre-treated gynecologic tumors. Lunresertib shows potential as a clinical-stage PKMYT1 inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
clinical trial
News

Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Rhea-AI Summary
Repare Therapeutics to share initial data from Phase 1 MYTHIC clinical trial at upcoming conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.58%
Tags
conferences clinical trial
Stock RPTX logo
Repare Therapeutics Inc.

Nasdaq:RPTX

RPTX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

RPTX Stock Data

51.01M
38.66M
0.98%
80.17%
2.49%
Biotechnology
Pharmaceutical Preparations
Link
Canada
SAINT-LAURENT